

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**


(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	09/996,069 ✓	
	Filing Date	November 27, 2001	
	First Named Inventor	BAMDAD, Cynthia C.	
	Art Unit	1645	
	Examiner Name	N/A	
Total Number of Pages in This Submission	9	Attorney Docket Number	M1015.70071

**ENCLOSURES (Check all that apply)**


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): PTO/SB/08A, PTO/SB/08B and copies of the cited references A1-13, B1-B12, C1-C17; and Return Receipt Postcard
<b>Remarks</b> Total Number of Pages in Submission does not include references.		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	Joseph Hyosuk Kim, Ph.D. Reg. No. 41,425 JHK Law
Signature	
Date	November 4, 2005

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Harry Sung Lee		
Signature		Date	November 4, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT

I hereby certify that on November 4, 2005, which is the date I am signing this certificate, I am depositing this correspondence and all identified attachments with the U.S. Postal Service, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Harry Lee

Applicant: **BAMDAD, Cynthia C.**Serial No.: **09/996,069**Filed: **November 27, 2001**Confirmation No.: **1136**Title: **DIAGNOSTIC TUMOR  
MARKERS, DRUG SCREENING FOR  
TUMORIGENESIS INHIBITION, AND  
COMPOSITIONS AND METHODS FOR  
TREATMENT OF CANCER**Examiner: **N/A**Art Unit: **1645**Attorney Docket No.: **M1015-70071****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents are enclosed.

**English Language Documents:**

US 3,854,480, ZAFFARONI, December 17, 1974
US 4,452,775, KENT, June 5, 1984
US 4,675,189, KENT et al., June 23, 1987



US 5,075,109, TICE et al., December 24, 1991
US 5,133,974, PARADISSIS et al., July 28, 1992
US 5,407,686, PATEL et al., April 18, 1995
US 5,736,152, DUNN, April 7, 1998
US 6,127,393, FERNANDEZ-POL, October 3, 2000
US 6,548,643 B1, MCKENZIE et al., April 15, 2003
US 2003/0130293 A1, BAMDAD, July 10, 2003
US 2003/0119834 A1, BAMDAD, June 26, 2003
US 2002/0156112 A1, BAMDAD et al., October 24, 2002
U.S. Application No. 09/631,818, BAMDAD, filing date of August 3, 2000 (abandoned)
WO 95/24929 A2, MATHIOWITZ et al., September 21, 1995 (with English abstract)
WO 00/34783 A1, BERGSMA et al., June 15, 2000
WO 00/43791 A2, BAMDAD et al., July 27, 2000
WO 02/056022 A2, BAMDAD et al., July 18, 2002
WO 02/078598 A2, WRESCHNER et al., October 10, 2002
WO 02/22685 A2, KUFE et al., March 21, 2002
WO 03/020279 A2, BAMDAD, March 13, 2003
WO 03/020280 A2, BAMDAD, March 13, 2003
WO 03/089451 A2, HOOGENBOOM et al., October 30, 2003
WO 2004/005470 A2, PAYNE et al., January 15, 2004
WO 2005/019269 A2, BAMDAD, March 3, 2005
MEERZAMAN et al., "Involvement of the MAP kinase ERK2 in MUC1 mucin signaling", <i>Am. J. Physiol. Lung Cell Mol. Physiol.</i> (2001), 281: L86-L91
SPICER et al., "Molecular Cloning and Analysis of the Mouse Homologue of the Tumor-associated Mucin, MUC1, Reveals Conservation of Potential O-Glycosylation Sites, Transmembrane, and Cytoplasmic Domains and a Loss of Minisatellite-like Polymorphism", <i>The Journal of Biological Chemistry</i> (1991), 266(23): 15099-15109
VARNER et al., "Integrins and cancer", <i>Current Opinion in Cell Biology</i> (1996), 8: 724-730
HORTON, "The $\alpha\beta 3$ Integrin "Vitronectin Receptor", <i>Int. J. Biochem. Cell Biol.</i> (1997), 29(5): 721-725
ROSS et al., "The HER-2/ <i>neu</i> Oncogene in breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy", <i>Stem Cells</i> (1998), 16: 413-428
TREON et al., "MUC-1 Core Protein is Expressed on Multiple Myeloma Cells and is Induced by Dexamethasone", <i>Blood</i> (1999), 93(4): 1287-1298
LIGTENBERG et al., "Cell-associated Episialin is a Complex Containing Two Proteins Derived from a Common Precursor", <i>The Journal of Biological Chemistry</i> (1992), 267(9): 6171-6177
CHEN et al., "Labeling of Proteins with [ $^{35}$ S]Methionine and/or [ $^{35}$ S]Cysteine in the Absence of Cells", <i>Analytical Biochemistry</i> (1999), 269: 179-188
SAWHNEY et al., "Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly( $\alpha$ -hydroxy acid) Diacrylate Macromers", <i>Macromolecules</i> (1993), 26: 581-587

HIEKEN et al., "beta3 Integrin Expression in Melanoma Predicts Subsequent Metastasis", <i>Journal of Surgical Research</i> (1996): 63(1): 169-173(5) (abstract only)
VAILHE et al., "In vitro angiogenesis is modulated by the mechanical properties of fibrin gels and is related to alpha(v)beta3 integrin localization", <i>In Vitro Cell Dev. Biol. Anim.</i> (1997), 33(10): 763-773 (abstract only)
PEGRAM et al., "Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment", <i>Journal of Clinical Oncology</i> (1998), 16: 2659-2671 (abstract only)
FRALEY et al., "New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids", <i>Trends in Biochemical Sciences</i> (1981), 6: 77-80 (abstract only)
KUFE et al., "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors", <i>Hybridoma</i> (1984), 3(3): 223-232 (abstract only)
SCHNEIDER et al., "nm23 expression in advanced and borderline ovarian carcinoma", <i>Anticancer Res.</i> (1996), 16(3A): 1197-1202 (abstract only)
MAO et al., "Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer", <i>Int. J. Oncol.</i> (2001), 18(3): 587-591 (abstract only)
GREGORIADIS, "Liposomes for drugs and vaccines", <i>Trends in Biotechnology</i> (1985), 3(9): 235-241 (abstract only)

Foreign Language Document:

WO 92/07000A1, CHAMBON et al., April 30, 1992 (with English abstract)
-----------------------------------------------------------------------

It is respectfully requested that the Examiner indicate consideration of the cited references by returning copies of the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) with initials or other appropriate marks, and that the references be made of record as cited references in the application.

This Information Disclosure Statement is being filed before the mailing date of a First Office Action on the merits in the above-identified case. Therefore, no fee is required.

The Commissioner is authorized to charge JHK Law's Deposit Account No. **502486** for any fees required under 37 CFR §§ 1.16 and 1.17 and to credit any overpayment to said Deposit Account No. **502486**.

Respectfully submitted,

Har Lee, Reg. No. 56,814

November 4, 2005

Date

Joseph Hyosuk Kim, Ph.D.

Reg. No. 41,425

Attorney for Applicants


**JHK Law**

P.O. Box 1078

La Canada, CA 91012-1078

Telephone: (818) 249-8177

Facsimile: (818) 249-8277



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

2

**Complete if Known**

Application Number	09/996,069
Filing Date	November 27, 2001
First Named Inventor	BAMDAD, Cynthia C.
Art Unit	1645
Examiner Name	N/A
Attorney Docket Number	M1015.70071

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	US- 3,854,480	12-17-1974	ZAFFARONI	whole document
	A2	US- 4,452,775	06-05-1984	KENT	whole document
	A3	US- 4,675,189	06-23-1987	KENT et al.	whole document
	A4	US- 5,075,109	12-24-1991	TICE et al.	whole document
	A5	US- 5,133,974	07-28-1992	PARADISSIS et al.	whole document
	A6	US- 5,407,686	04-18-1995	PATEL et al.	whole document
	A7	US- 5,736,152	04-07-1998	DUNN	whole document
	A8	US- 6,127,393	10-03-2000	FERNANDEZ-POL	whole document
	A9	US- 6,548,643 B1	04-15-2003	MCKENZIE et al.	whole document
	A10	US- 2003/0130293 A1	07-10-2003	BAMDAD	whole document
	A11	US- 2003/0119834 A1	06-26-2003	BAMDAD	whole document
	A12	US- 2002/0156112 A1	10-24-2002	BAMDAD et al.	whole document
	A13	US- 09/631,818 (08-03-2000)		BAMDAD	whole document
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	WO 92/07000	04-30-1992	CHAMBON et al.	whole document	<input checked="" type="checkbox"/>
	B2	WO 95/24929	09-21-1995	MATHIOWITZ et al.	whole document	<input type="checkbox"/>
	B3	WO 00/34783	06-15-2000	BERGSMA et al.	whole document	<input type="checkbox"/>
	B4	WO 00/43791	07-27-2000	BAMDAD et al.	whole document	<input type="checkbox"/>
	B5	WO 02/056022 A2	07-18-2002	BAMDAD et al.	whole document	<input type="checkbox"/>
	B6	WO 02/078598 A2	10-10-2002	WRESCHNER et al.	whole document	<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/996,069
Filing Date	November 27, 2001
First Named Inventor	BAMDAD, Cynthia C.
Art Unit	1645
Examiner Name	N/A
Attorney Docket Number	M1015.70071

Sheet 1 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	MEERZAMAN et al., "Involvement of the MAP kinase ERK2 in MUC1 mucin signaling", Am. J. Physiol. Lung Cell Mol. Physiol. (2001), 281: L86-L91	
	C2	SPICER et al., "Molecular Cloning and Analysis of the Mouse Homologue of the Tumor-associated Mucin, MUC1, Reveals Conservation of Potential O-Glycosylation Sites, Transmembrane, and Cytoplasmic Domains and a Loss of Minisatellite-like Polymorphism", The Journal of Biological Chemistry (1991), 266(23): 15099-15109	
	C3	VARNER et al., "Integrins and cancer", Current Opinion in Cell Biology (1996), 8: 724-730	
	C4	HORTON, "The avb3 Integrin "Vitronectin Receptor", Int. J. Biochem. Cell Biol. (1997), 29(5): 721-725	
	C5	ROSS et al., "The HER-2/neu Oncogene in breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy", Stem Cells (1998), 16: 413-428	
	C6	TREON et al., "MUC-1 Core Protein is Expressed on Multiple Myeloma Cells and is Induced by Dexamethasone", Blood (1999), 93(4): 1287-1298	
	C7	LIGTENBERG et al., "Cell-associated Episialin is a Complex Containing Two Proteins Derived from a Common Precursor", The Journal of Biological Chemistry (1992), 267(9): 6171-6177	
	C8	CHEN et al., "Labeling of Proteins with [35S]Methionine and/or [35S]Cysteine in the Absence of Cells", Analytical Biochemistry (1999), 269: 179-188	
	C9	SAWHNEY et al., "Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly(a-hydroxy acid) Diacrylate Macromers", Macromolecules (1993), 26: 581-587	
	C10	HIEKEN et al., "beta3 Integrin Expression in Melanoma Predicts Subsequent Metastasis", Journal of Surgical Research (1996): 63(1): 169-173(5)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/996,069
Filing Date	November 27, 2001
First Named Inventor	BAMDAD, Cynthia C.
Art Unit	1645
Examiner Name	N/A
Attorney Docket Number	M1015.70071

Sheet

2

of

2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C11	VAILHE et al., "In vitro angiogenesis is modulated by the mechanical properties of fibrin gels and is related to alpha(v)beta3 integrin localization", In Vitro Cell Dev. Biol. Anim. (1997), 33(10): 763-773	
	C12	PEGRAM et al., "Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment", Journal of Clinical Oncology (1998), 16: 2659-2671	
	C13	FRALEY et al., "New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids", Trends in Biochemical Sciences(1981), 6: 77-80	
	C14	KUFE et al., "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors", Hybridoma (1984), 3(3): 223-232	
	C15	SCHNEIDER et al., "nm23 expression in advanced and borderline ovarian carcinoma", Anticancer Res. (1996), 16(3A): 1197-1202	
	C16	MAO et al., "Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer", Int. J. Oncol. (2001), 18(3): 587-591	
	C17	GREGORIADIS, "Liposomes for drugs and vaccines", Trends in Biotechnology (1985), 3(9): 235-241	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.